Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners. - Wikidata - wikimedia - TriplyDB

Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners.

Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners.

http://www.wikidata.org/entity/Q42677475

about

(-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases Characterization of the DNA-binding domain and identification of the active site residue in the 'Gyr A' half of Leishmania donovani topoisomerase II A gene expression database for the molecular pharmacology of cancer Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases.The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing Molecular analysis of yeast and human type II topoisomerases. Enzyme-DNA and drug interactions.Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site.

P2860

Q24627296-3D0F89DC-7D0E-4321-8FA2-4C02D4764374 Q24793787-E9DB6AA0-3D5C-499A-AEA8-E01B8BB0B559 Q29619242-FFF7FAFF-B06A-4037-ACF0-8C1C22FD1F01 Q34565690-829DBCD0-ACD8-42CD-89AF-E8A0DB433E8D Q35838855-112F54F8-D805-4192-BC74-8458C8F3A7F2 Q37108461-C8DDF8F0-D581-48AE-A7F6-E9B0041EA680 Q38320285-87598236-300F-4616-8380-5303866251A4 Q45230495-3E0EF595-956A-4EF3-B0E0-4E59C52D4A0F

P2860

Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners.

http://www.wikidata.org/entity/Q42677475

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

1998年论文

@zh

1998年论文

@zh-cn

name

Mapping drug interactions at t ...... isantrene/amsacrine congeners.

@en

Mapping drug interactions at t ...... isantrene/amsacrine congeners.

@nl

type

label

Mapping drug interactions at t ...... isantrene/amsacrine congeners.

@en

Mapping drug interactions at t ...... isantrene/amsacrine congeners.

@nl

prefLabel

Mapping drug interactions at t ...... isantrene/amsacrine congeners.

@en

Mapping drug interactions at t ...... isantrene/amsacrine congeners.

@nl

P1433

Q42677475-45B561A9-7FC9-4F5A-9F2E-D3D3458166C1

P1476

Q42677475-3EAFA3FC-F135-462E-8B7A-C6FFB41D9072

P2093

Q42677475-77626F06-F35F-4C48-8D20-60497643C0AA

Q42677475-80F6DFCD-4DAB-491C-9479-D23AFB9B9FC0

Q42677475-96A542B3-F165-448D-8853-2FC3CF20B083

Q42677475-BC20FB8E-F00B-4551-B220-0E4DD9D24BAB

Q42677475-F3617CC9-E4F2-4031-A7B3-AE67C512B225

P2860

Q42677475-0032A9C6-74D3-466E-904C-589A0C6AF067

Q42677475-34090C8C-3BF8-4857-82E8-99CB46F6EED0

Q42677475-43C53C91-7585-4F59-9B8C-8E9098FE5362

Q42677475-73264729-25C3-4C48-8859-DABE15257A42

Q42677475-7427F209-704D-4CE9-9734-272269599DFC

Q42677475-9C6C3612-D450-4E8E-A6BF-293FBE27CBED

Q42677475-B1424456-64BD-40BC-81B0-1245E4015C78

Q42677475-BD116975-DCD4-4E0A-B29C-288FA94203AA

Q42677475-C4460527-258B-4AE0-B798-C38406A90D0E

Q42677475-C5615219-AE22-405A-875D-3383ECB96299

P304

Q42677475-8724C01A-9972-435D-88F3-B3A26DA58ABC

P31

Q42677475-8ACE2AF9-97F1-4F1A-8462-62FCBAE56C55

P356

Q42677475-4DF7E3A6-4F9A-4070-B023-78EC2813E61E

P407

Q42677475-6E4131B0-659E-4B93-9B04-E46C25A3F397

P433

Q42677475-D53A23C6-71D3-4B5C-BE1B-C204072BE639

P478

Q42677475-20F8B7F2-D755-4E5F-B669-31B5E21EB61F

P50

Q42677475-3FBD19E1-E8C3-48A2-BA12-6E9391202BA5

Q42677475-436A399D-20B4-4686-B09E-FD570A84007F

Q42677475-58B83549-C367-4707-BF92-DAE8BE6839B6

Q42677475-AB9AE38F-A4F7-4EA0-A876-21765784FFCE

P577

Q42677475-DA61CBAB-469A-4ABD-8F42-72865E5533C1

P5875

Q42677475-C9196682-B8CA-4929-88F7-BE09D9F6C868

P698

Q42677475-B12CF520-9BA6-4E7C-8708-0C47669827F3

P356

JBC.273.21.12732

P1433

Journal of Biological Chemistry

P1476

Mapping drug interactions at t ...... bisantrene/amsacrine congeners

@en

P2093

C Sissi

http://www.w3.org/2001/XMLSchema#string

E Menta

http://www.w3.org/2001/XMLSchema#string

F Guano

http://www.w3.org/2001/XMLSchema#string

F Zunino

http://www.w3.org/2001/XMLSchema#string

G Zagotto

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and function of type II DNA topoisomerases

Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model

DNA topoisomerases

Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites

Base sequence determinants of amonafide stimulation of topoisomerase II DNA cleavage.

Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide.

Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.

Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.

Energetics and stereochemistry of DNA complexation with the antitumor AT specific intercalators tilorone and m-AMSA

Catalytic function of DNA topoisomerase II.

P304

12732-12739

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.273.21.12732

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

273

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Capranico

P577

1998-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13702374

http://www.w3.org/2001/XMLSchema#string

P698

9582297

http://www.w3.org/2001/XMLSchema#string